FrancophonIA/ELRC3.0 huggingface dataset:
English: the CHMP has recommended the granting of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Lansoprazol ratiopharm and associated names (see Annex I).
Estonian: ¾ taotleja pakutud ravimi omaduste kokkuvõtet, märgistust ja pakendi infolehte on hinnatud esitatud dokumentide põhjal ja teadusliku arutelu käigus inimtervishoius kasutatavate ravimite komitees; on inimtervishoius kasutatavate ravimite komitee soovitanud anda müügiload Lansoprazol ratiopharm'ile ja sellega seotud nimetustele (vt I lisa), mille ravimiomaduste kokkuvõte, märgistus ja pakendi infoleht on esitatud III lisas.
English: What Lansoprazol-ratiopharm contains
Estonian: Mida Lansoprazol-ratiopharm sisaldab
English: In case of clarithromycin resistance, or treatment failure, the combination of lansoprazole-amoxicillinmetronidazole may be used, and in case of beta-lactam allergy the combination of lansoprazoleclarithromycin-metronidazole is advisable.
Estonian: Kui patsient on klaritromütsiini suhtes resistentne või ei allu selle toimele, võib kasutada lansoprasooli-amoksitsilliini-metronidasooli kombinatsiooni,
English: < Lansoprazol-ratiopharm and associated names (see Annex I) 30 mg magensaftresistente Hartkapseln > Lansoprazol
Estonian: < Lansoprazol-ratiopharm ja sarnased nimed (vaata I Lisa) 30 mg maohappekindlad kõvakapslid > Lansoprasool
English: Gastrointestinal disorders
Estonian: Gastroresistentsed kõvakapslid Peroraalne
English: HOW TO TAKE Lansoprazol-ratiopharm
Estonian: “Kuidas kasutada Lansoprazol-ratiopharm
English: The effect of the following medicines or drug groups may be influenced by Lansoprazol-ratiopharm if they are used at the same time:
Estonian: Samaaegsel kasutamisel võib Lansoprazol-ratiopharm mõjutada järgmiste ravimite või ravimgruppide toimeid
English: Please consult your doctor before taking Lansoprazol-ratiopharm if you know that you are intolerant to certain sugars.
Estonian: Kui te teate, et te ei talu teatud suhkruid, palun konsulteerige enne Lansoprazol-ratiopharm'i kasutamist oma arstiga.
English: How to store Lansoprazol-ratiopharm Further information
Estonian: Kuidas Lansoprazol-ratiopharm'i säilitada Lisainfo
English: Helicobacter pylori eradication:
Estonian: pylori eradikatsioonravi annustamise suhtes;
English: HOW TO STORE Lansoprazol-ratiopharm
Estonian: KUIDAS Lansoprazol-ratiopharm'i SÄILITADA
English: NAME OF THE MEDICINAL PRODUCT < Lansoprazol-ratiopharm and associated names (see Annex I) 30 mg magensaftresistente Hartkapseln > lansoprazole
Estonian: RAVIMPREPARAADI NIMETUS < Lansoprazol-ratiopharm ja sarnased nimed (vaata I Lisa) 30 mg maohappekindel kõvakapsel> [vaata I Lisa - täidetakse riiklikult]
English: NAME OF THE MEDICINAL PRODUCT < Lansoprazol-ratiopharm and associated names (see Annex I) 15 mg magensaftresistente Hartkapseln > lansoprazole
Estonian: RAVIMPREPARAADI NIMETUS < Lansoprazol-ratiopharm ja sarnased nimed (vaata I Lisa) 15 mg maohappekindel kõvakapsel> [vaata I Lisa - täidetakse riiklikult]
English: Sweden ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Rootsi ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: Germany ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Saksamaa ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: Luxembourg ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Luksemburg ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: Italy ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Itaalia ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: Denmark ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Taani ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: It is available in all European Member States.
Estonian: Seda turustatakse kõigis Euroopa Liidu liikmesriikides.
English: Zometa has been authorised since March 2001.
Estonian: Zometa sai müügiloa 2001. aasta märtsist.
English: The full European Public Assessment Report for Zometa can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zometa kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports
English: The study included 1,803 women previously treated with surgery who received Zometa every six months for three years, and were followed up for five years.
Estonian: Uuring hõlmas 1803 naist, keda oli varem kirurgiliselt ravitud ja kes said kolme aasta vältel iga kuue
English: Early breast cancer is breast cancer that has not spread and has been treated by surgery.
Estonian: Varane rinnavähk on vähk, mis ei ole rinnanäärmest edasi levinud ja mida on kirurgiliselt ravitud.
English: On 14 December 2010, Novartis Europharm Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Zometa, in the treatment of early breast cancer in premenopausal women.
Estonian: 14. detsembril 2010 teatas Novartis Europharm Limited ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Zometa uue näidustuse taotlus.
English: The study measured ‘disease-free survival' (how long the patients lived without cancer).
Estonian: Uuringus hinnati haigusvaba elulemust (see näitab, kui kaua patsiendid ilma vähita elasid).
English: What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?
Estonian: Kuidas mõjutab taotluse tagasivõtmine praegu kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente?
English: The study compared anastrozole and tamoxifen (medicines used in hormone-receptor positive breast cancer) with or without Zometa.
Estonian: Uuringu vältel manustati anastrosooli ja tamoksifeeni (hormoonretseptorpositiivse rinnavähi korral kasutatavad ravimid) koos Zometaga või ilma.
English: Zometa is a medicine that contains the active substance zoledronic acid.
Estonian: Zometa on ravim, mis sisaldab toimeainena zoledroonhapet.
English: By blocking this enzyme, it was expected to prevent the growth of cancer cells and cause their death.
Estonian: Nimetatud ensüümi blokeerimise tõttu arvati, et zoledroonhape takistab kasvajarakkude arengut ja kutsub esile nende surma.
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Estonian: Ettevõtte kiri, milles ta teatab inimravimite komiteele oma taotluse tagasivõtmisest, on avaldatud jaotises „All documents“.
English: The Committee also had concerns regarding the reliability of the data collected during the study.
Estonian: Peale selle oli inimravimite komiteel kahtlusi uuringus kogutud andmete usaldusväärsuse kohta.
English: It is approved for use as a drip into a vein every three to four weeks to prevent bone complications such as fractures in adults with advanced cancer that is affecting the bone.
Estonian: Zometa on heaks kiidetud veeni tilgutatavaks tilkinfusiooniks iga kolme kuni nelja nädala tagant, et ära hoida luukude haarava kaugelearenenud vähi luutüsistusi, näiteks luumurde.
English: The study was ‘open label': both the doctor and the patient knew which treatment they were using.
Estonian: See tähendab, et nii arst kui ka patsient teadsid, mis ravi uuringus kasutati.
English: Zoledronic acid, the active substance in Zometa, blocks an enzyme called ‘farnesyl pyrophosphate synthase'.
Estonian: Zometa toimeaine zoledroonhape blokeerib ensüümi nimega farnesüülpürofosfataasi süntaas.
English: Based on the review of the data and the company's responses to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Zometa could not have been approved for the adjuvant treatment of early breast cancer.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõte vastustele inimravimite komitee esitatud küsimustele, nägi komitee tagasivõtmise ajal põhjuseid ettevaatlikkuseks ja oli esialgsel arvamusel, et Zometat ei saa varase rinnavähi abistavaks raviks heaks kiita.
English: The company informed the CHMP that this withdrawal does not an impact on ongoing clinical trials with Zometa.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta Zometa käimasolevaid kliinilisi uuringuid.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the medicine could not have been approved based on the data presented by the company.
Estonian: Seetõttu oli inimravimite komitee taotluse tagasivõtmise ajal arvamusel, et ettevõtte esitatud andmete alusel ei ole võimalik ravimi kasutamist heaks kiita.
English: Zometa can also be used to treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.
Estonian: Zometat võib samuti kasutada kasvajast tingitud hüperkaltseemia (suur kaltsiumisisaldus veres) raviks.
English: Zometa was only to be used if the breast cancer was ‘hormone receptor positive' (the cancer is likely to respond to hormonal treatment), and in combination with hormonal treatment.
Estonian: Zometat plaaniti kasutada üksnes hormoonretseptorpositiivse vähi (see on vähk, mis tõenäoliselt reageerib hormoonravile) korral kombinatsioonis hormoonraviga.
English: The company provided data from one main study to support the use of Zometa in early breast cancer.
Estonian: Ettevõte esitas Zometa kasutamise toetuseks varase rinnavähi ravis ühe põhilise uuringu andmed.
English: The way Zometa is expected to works in early breast cancer is not fully elucidated.
Estonian: Zometa eeldatav toimemehhanism varase rinnavähi korral ei ole päris selge.
English: Zometa was expected to be used as an adjuvant (add-on) in the treatment of early breast cancer in women who have not been through the menopause.
Estonian: Zometat plaaniti kasutada varase rinnavähi abistava (täiendava) ravimina naistel, kellel ei ole veel saabunud menopaus.
English: The Committee noted that the treatments used in the control groups to which Zometa was compared were not all representative of the standards of care in Europe.
Estonian: Nimelt leidis inimravimite komitee, et kontrollrühmades kasutatud ravimid, millega Zometat võrreldi, ei vastanud täielikult Euroopa ravistandardile.
English: It also had concerns regarding the way the study in early breast cancer had been carried out.
Estonian: Samuti oli inimravimite komiteel kahtlusi varase rinnavähiga naistel läbi viidud uuringu suhtes.
English: What is happening with Zometa for the prevention of bone events in cancer patients?
Estonian: Kuidas mõjutab taotluse tagasivõtmine Zometa kasutamist luutüsistuste ärahoidmiseks vähihaigetel patsientidel?
English: All women also received goserelin, a medicine that suppresses the activity of the ovaries.
Estonian: Peale selle said kõik naised uuringus veel gosereliini.
English: There are no consequences on the use of Zometa in its authorised indications.
Estonian: Antud taotluse tagasivõtmine ei mõjuta Zometa kasutamist juba heakskiidetud näidustustel.
English: The Committee had concerns that the anti-tumour activity of Zometa when used as add-on had not been sufficiently supported by the data from the study.
Estonian: Inimravimite komitee leidis, et Zometa kasvajavastane toime kasutamisel abistava ravimina ei olnud uuringu andmete alusel piisaval määral tõendatud.
English: Studies and Reviews
Estonian: Uuringud ja läbivaatamine
English: Communication
Estonian: Teabevahetus
English: Particular attention should be given to indication, dosage and duration of treatment.
Estonian: Erilist tähelepanu pööratakse näidustusele, annustamisele ja ravi kestusele.
English: This retrospective study should lead to a follow-up prospective study in transplant centres.
Estonian: Retrospektiivsele uuringule järgneb perspektiivuuring siirdamiskeskustes.
English: Further updates of the Risk Management Plan should be submitted for assessment at national level.
Estonian: Riskijuhtimiskava uuendused esitatakse riikliku tasandi hindamiseks.
English: The final study reports of the above studies should be submitted to the National Competent Authorities for assessment.
Estonian: Eespool nimetatud uuringute lõplikud aruanded esitatakse hindamiseks liikmesriikide pädevatele asutustele.
English: The communication shall include comprehensive information on the safety risks associated with the use of nimesulide.
Estonian: Teatises on nimesuliidi kasutamise ohutusriskide üksikasjalik teave.
English: • The MAHs should conduct a pre-clinical study on identification of reactive metabolites and protein adduct information.
Estonian: • Müügiloa hoidja teeb reaktiivsete metaboliitide tuvastamise ja proteiinaduktide teabe eelkliinilise uuringu.
English: • The MAHs should perform a survey to clarify the modes of use of nimesulide in selected EU Member States to identify potential misuse.
Estonian: • Müügiloa hoidja teeb uuringu nimesuliidi kasutusviiside väljaselgitamiseks teatud Euroopa Liidu liikmesriikides, et tuvastada võimalikku väärkasutamist.
English: Competent authorities for assessment within one year after adoption of the Commission Decision.
Estonian: Liikmesriikide pädevatele asutustele esitatakse aruanne hindamiseks ühe aasta jooksul pärast komisjoni otsuse vastuvõtmist.
English: A report should be provided to the National Competent authorities for assessment every 6 months as part of the PSUR (starting within one semester after adoption of the Commission Decision).
Estonian: Liikmesriikide pädevatele asutustele esitatakse aruanne hindamiseks perioodilise ohutusaruande osana iga kuue kuu järel (esimene aruanne esitatakse komisjoni otsuse vastuvõtmisele järgneva kuue kuu jooksul).
English: Post-marketing surveillance
Estonian: Turustamisjärgne seire
English: The protocol should be submitted to the CHMP by 3 months after the completion of the final study report of the retrospective study for review and agreement.
Estonian: Aruanne esitatakse läbivaatamiseks ja heakskiidu saamiseks inimravimite komiteele kolme kuu jooksul pärast retrospektiivse uuringu lõpliku aruande valmimist.
English: The MAHs should strengthen the medical review, refine the monitoring of reporting rates, and improve the quality of Individual Case Safety Reports of nimesulide.
Estonian: Müügiloa hoidja parandab nimesuliidi meditsiinilist läbivaatamist, juhtudest teatamise järelevalvet ja üksikjuhtumite ohutusaruannete kvaliteeti.
English: Hepatic reactions should be given cumulatively and for the period covered by the PSUR.
Estonian: Maksareaktsioonid esitatakse kumulatiivselt ja perioodilise ohutusaruandega hõlmatud ajavahemiku kohta.
English: • The MAHs should submit a revised Risk Management Plan for nimesulide, considering the comments raised during this procedure, to the CHMP.
Estonian: • Müügiloa hoidja esitab inimravimite komiteele nimesuliidi läbivaadatud riskijuhtimiskava, võttes arvesse menetluse ajal esitatud märkusi.
English: The draft DHPC should be submitted to the CHMP within one month after adoption of the Commission Decision.
Estonian: Tervishoiu töötajate teatise kavand esitatakse inimravimite komiteele üks kuu pärast komisjoni otsuse vastuvõtmist.
English: • The MAHs should conduct a review of epidemiological data to review the risk of hepatic damage from nimesulide in comparison with other NSAIDs
Estonian: • Müügiloa hoidja vaatab läbi epidemioloogilised andmed, et kontrollida nimesuliidist tingitud maksakahjustuse riske võrrelduna teiste mittesteroidsete põletikuvastaste ravimitega (NSAID).
English: • The MAHs should inform healthcare professionals on the outcome of this review on nimesulide via a “Direct Healthcare Professional Communication” (DHPC) to be agreed with the CHMP.
Estonian: • Müügiloa hoidja teatab tervishoiu töötajaile nimesuliidi läbivaatamise tulemused tervishoiu töötajate teatises, mille sisu lepitakse kokku inimravimite komiteega.
English: The following conditions in relation to post-marketing surveillance, studies and review and communication shall be fulfilled by the Marketing Authorisation Holders of nimesulide containing medicinal products (systemic formulation).
Estonian: Nimesuliidi sisaldavate ravimite (süsteemne ravimvorm) müügiloa hoidjad täidavad järgmised allpool toodud tingimused: turustamisjärgne seire, uuringud, läbivaatamine ja teabevahetus.
English: These PSURs should be submitted to the National Competent Authorities for assessment.
Estonian: Perioodilised ohutusaruanded esitatakse hindamiseks liikmesriikide pädevatele asutustele.
English: This study should address the relative risk of nimesulide in respect to other NSAIDs to cause severe hepatic reactions leading to transplants.
Estonian: • Müügiloa hoidja korraldab siirdamiskeskustes retrospektiivse kohortuuringu, mis käsitleb nimesuliidi suhtelist riski võrrelduna teiste NSAID-ravimitega selliste raskete maksa kõrvalnähtude põhjustamisel, mille korral on vaja siirdamist.
English: • The MAHs should perform a monitoring activity to evaluate the effectiveness of risk communication on nimesulide.
Estonian: • Müügiloa hoidja jälgib nimesuliidi riskidest teatamise efektiivsust, et seda hinnata.
English: The MAHs should expedite and submit all safety reports and case series in PSURs for nimesulide, with a six monthly periodicity.
Estonian: Müügiloa hoidja esitab viivitamata iga kuue kuu järel koostatavas nimesuliidi perioodilises ohutusaruandes kõik ohutusaruanded ja juhtumikirjeldused.
English: These PSURs should include a specific overview of the hepatic reactions.
Estonian: Perioodilised ohutusaruanded sisaldavad muu hulgas maksareaktsioonide eriülevaadet.
English: Medicinal product no longer authorised
Estonian: Ravim il on üügiluba lõppenud
English: ETHYPHARM 17/21 rue Saint-Matthieu 78550 Houdan
Estonian: ETHYPHARM 17/21 rue SaintMatthieu 78550 Houdan
English: 1 ml (120 mg/ml) 1 pre-filled pen + 2 alcohol pads
Estonian: 1 pen-süstel + 2 alkoholipadjakesega
English: MYLAN SAS 117 allée des Parcs 69800 SAINT PRIEST FRANCE
Estonian: Prantsusmaa MYLAN SAS 117 allée des Parcs 69800 Saint Priest France
English: em., H-1036 Budapest Hungary
Estonian: H-1036 Budapest Hungary
English: RANBAXY PHARMACIE GENERIQUES
Estonian: Prantsusmaa Ranbaxy Pharmacie Generiques
English: 110 Esplanade du Général de Gaulle
Estonian: Prantsusmaa Teva Sante 110 Esplanade du Général de Gaulle
English: 92931 PARIS LA DEFENSE FRANCE
Estonian: 92931 Paris la Defence France
English: 28108 Alcobendas (Madrid) Spain
Estonian: 28108 Alcobendas Madrid
English: SANOFI AVENTIS FRANCE 1-13 BOULEVARD ROMAIN ROLLAND
Estonian: Prantsusmaa Sanofi Aventis France 1-13 Boulevard Romain Rolland
English: 13353 Berlin
Estonian: D-13353 Berlin
English: Rua Quinta Pinheiro, 5, Outurela - Carnaxide
Estonian: Rua Quinta Pinheiro, 5, Outurela
English: LADEEPHARMA PHARMACEUTICAL Limited Lajos u. 48-66, E ép.
Estonian: Ladeepharma Pharmaceutical Limited Lajos u. 48-66
English: MAROUSSI GR-15125 ATHENS
Estonian: Athens GR-15125 Greece
English: Osa Mayor, 4 28023 Aravaca (Madrid) Spain
Estonian: Osa Mayor, 4 28023 Aravaca Madrid
English: Ilford, Essex IG3 8BS
Estonian: Essex IG3 8BS
English: TEVA PHARMA, SLU Anabel Segura 11, Edificio Albatros B, 1ª planta 28108 Alcobendas (Madrid) Spain
Estonian: Teva Pharma, SLU Anabel Segura 11 Edificio Albatros B 1ª planta 28108 Alcobendas Madrid
English: Sandoz d.d Verovskova 57, 1000 Ljubljana
Estonian: Sandoz d.d Verovskova 57 1000 Ljubljana Slovenia
English: CHEMICAL FARMA 19-23 rue d'Hautpoul 75019 PARIS FRANCE
Estonian: Prantsusmaa CHEMICAL FARMA 19-23 rue d'Hautpoul 75019 Paris
English: Comprimidos
Estonian: Tablett
English: DCI PHARMA 180 RUE EUGENE AVINEE 59120 LOOS
Estonian: Prantsusmaa DCI Pharma 180 Rue Eugene Avinee 59120 Loos
English: List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for cyproterone acetate/ethinylestradiol containing medicinal products
Estonian: Lisa I Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside, Müügiloa hoidjate loetelu liikmesriikides
English: Berlifarma - Especialidades Farmaceuticas, Lda.
Estonian: BerlifarmaEspecialidades Farmaceuticas, Lda.
English: United Kingdom Fannin (UK) Limited, 42-46 Booth Drive, Park Farm
Estonian: Ühendkuningriik Fannin (UK) Limited 42-46 Booth Drive
English: EG LABO - LABORATOIRES EUROGENERICS 12 rue Danjou le Quintet bâtiment A 92517 BOULOGNE BILLANCOURT CEDEX FRANCE
Estonian: Prantsusmaa EG LABOLABORATOIRES EUROGENERICS 12 rue Danjou le Quintet bâtiment A 92517 Boulogne Billancourt Cedex France
English: United Kingdom Generics (UK) Limited, Station Close, Potters Bar, Hertfordshire EN6 1TL
Estonian: Generics (UK) Limited Station Close Potters Bar Hertfordshire EN6 1TL United Kingdom
English: Bayer S.p.A. Viale Certosa, 130 - 20156 Milano (MI) Italy
Estonian: Viale Certosa, 130 20156 Milano (MI) Italy
English: Parc d'Activités des Peupliers - 25 rue des Peupliers 92000 NANTERRE FRANCE
Estonian: 25 rue des Peupliers 92000 Nanterre
English: CYPROTERONE/ETHIN YLESTRADIOL BAYER 35 µg
Estonian: CYPROTERONE/ETHINYLESTRADIOL BAYER 35 µg
English: 3 DDD Pharma N.V. Diestersteenweg 349 3510 Hasselt Belgium
Estonian: Diestersteenweg 349 3510 Hasselt Belgium
English: Medico Uno Worldwide Ltd.,2 Grigori Afxentiou Street + Larnaca 6023
Estonian: 2 Grigori Afxentiou Street Larnaca 6023
English: United Kingdom Teva UK Limited, Brampton Road, Hampden Park,
Estonian: Ühendkuningriik Teva UK Limited Brampton Road
English: 49 avenue Georges Pompidou 92593 LEVALLOIS PERRET CEDEX
Estonian: 92593 Levallois Perret Cedex
English: United Kingdom Strandhaven Limited, 600 High Road, Seven Kings,
Estonian: Ühendkuningriik Strandhaven Limited 600 High Road
English: EFFIK bâtiment ''le Newton'' 9-11 rue Jeanne Braconnier 92366 MEUDON LA FORET FRANCE
Estonian: Prantsusmaa EFFIK bâtiment ''le Newton'' 9-11 rue Jeanne Braconnier
English: Jan Emiel Mommaertslaan 14 1831 Machelen Belgium
Estonian: Mommaertslaan 14 B-1831 Machelen Belgium
English: United Kingdom Bayer plc, Bayer House, strawberry Hill, Newbury, Berkshire RG14 1JA
Estonian: Strawberry Hill Newbury, Berkshire RG14 1JA,
English: United Kingdom Stragen UK Limited, Castle Court, 41 London Road,
Estonian: Stragen UK Limited Castle Court 41
English: United Kingdom Farmalider SA, Calle Aragoneses 15, Alcobendas, Madrid E-28108
Estonian: Farmalider S.A. Calle Aragoneses, 15 28108 Alcobendas Madrid
English: PIERRE FABRE DERMATOLOGIE 45 place Abel Gance 92100 BOULOGNE FRANCE
Estonian: Prantsusmaa Pierre Fabre Dermatologie 45, place Abel Gance
English: Marszałka J.Piłsudskiego 5 95-200 Pabianice Poland
Estonian: 95-200 Pabianice Poland
English: Poland acis Arzneimittel GmbH Lil-Dagover-Ring 7 82031 Grunwald Germany
Estonian: Acis Arzneimittel GmbH Lil-Dagover-Ring 7 82031 Grünwald Germany
English: Chloe 35 micrograms/2 mg film-coated tablets
Estonian: Chloe 35 micrograms/2 mg filmcoated tablets
English: LABORATOIRES MAJORELLE 80-82 rue Gallieni 92100 BOULOGNE BILLANCOURT FRANCE
Estonian: Prantsusmaa Laboratoires Majorelle 80-82 rue Gallieni
English: Diane 2000 micrograms/35 micrograms filmcoated tablets
Estonian: Diane 2000 micrograms/35 micrograms film-coated tablets
English: 220, avenue de la Recherche 59120 Loos
Estonian: 59120 Loos
English: Mithra Pharmaceuticals S.A. Rue Saint Georges 5 4000 Liège
Estonian: Rue Saint Georges 5 4000 Liège
English: Reigate, Surrey RH2 9RJ
Estonian: Reigate, Surrey RH2 PRJ United Kingdom
English: United Kingdom Sandoz Limited, Frimley Business Park, Frimley,
Estonian: Ühendkuningriik Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
English: Estonia ratiopharm GmbH Graf-Arco-Strasse 3 D-89079 Ulm Germany
Estonian: Ratiopharm GmbH Graf-Arco-Strasse 3 DE-89079 Ulm Germany
English: United Kingdom Chatfiled Pharmaceuticals Limited, Kramer Mews,
Estonian: Ühendkuningriik Chatfield Pharmaceuticals Limited
English: BAYER ΕΛΛΑΣ ΑΒΕΕ SOROU 18-20
Estonian: Bayer Hellas ABEE Sorou 18-20
English: South, Wellingborough, Kent NN8 6GT
Estonian: Kent NN8 6GT
English: 11-15 quai de Dion Bouton 92800 PUTEAUX FRANCE
Estonian: 11-15 quai de Dion
English: Castle Court 41, London Road, Reigate, Surrey RH2 PRJ,
Estonian: London Road Reigate, Surrey RH2 PRJ United Kingdom